Biocompatible coating for implantable medical devices

• US 8,871,883 B2
• Filed: 07/27/2010
• Issued: 10/28/2014
• Est. Priority Date: 12/11/2002
• Status: Expired due to Fees

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Claude, Charles D., Hossainy, Syed F. A., Michal, Eugene T.
• Primary Examiner(s): Choi, Ling
• Assistant Examiner(s): WANG, CHUN CHENG
• Application Number:
  US12/844,734
• Publication Number:
  US 20100292426A1
• Time in Patent Office: 1,554 Days
• Field of Search: 526/263, 526/287, 526/318.4, 526/320
• US Class Current: 526/263
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: C08L 33/06 of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical

Abstract

A copolymer which includes at least one biologically compatible structural moiety and at least one biologically active moiety is disclosed. The copolymer can be used for fabricating a coating for an implantable medical device such as a stent.

Claims

1. An implantable medical device comprising a coating, the coating including a copolymer, the copolymer comprising at least one structural block comprising at least one biologically compatible structural moiety included in its backbone and at least one biologically active block comprising at least one biologically active moiety attached in its backbone,

wherein the structural moiety comprises units derived from CH₂═

CX—

M;

wherein the biologically active block comprises units derived from a monomer selected from;

2-acrylamido-2-methyl-1-propanesulfonic acid,

poly(ethylene glycol) methacrylate,

3-sulfopropyl acrylate,

3-sulfopropyl methacrylate,

N-vinylpyrrolidone, and

acryloyl-, methacryloyl-, or 3-allyloxy-2-hydroxypropanesulfonic acid;

wherein the copolymer has a formula

2. The implantable medical device of claim 1, wherein when M or T is a substituted aryl group, the substituents in the aryl group are selected from a group consisting of halogens, hydroxyl, carboxyl and amino groups.

3. The implantable medical device of claim 1, wherein when R is a substituted aryl group, the substituents in the aryl group are selected from a group consisting of halogens, hydroxyl, carboxyl and amino groups.

4. A biologically compatible copolymer having a formula

5. The copolymer of claim 4, wherein when M or T is a substituted aryl group, the substituents in the aryl group are selected from a group consisting of halogens, hydroxyl, carboxyl and amino groups.

6. The copolymer of claim 4, wherein when R is a substituted aryl group, the substituents in the aryl group are selected from a group consisting of halogens, hydroxyl, carboxyl and amino groups.

7. A method for fabricating the copolymer of claim 4, wherein the copolymer is made by living free radical copolymerization of a plurality of monomers with initiation-transfer agent termination of living macro-chains.

8. The method of claim 7, wherein the monomers include monomers forming a structural moiety and monomers forming the biologically active moiety.

9. The method of claim 8, wherein the monomers forming the structural moiety comprise unsubstituted or substituted acrylates.

10. The method of claim 8, wherein the monomers forming the structural moiety are selected from a group consisting of methyl methacrylate, n-butyl methacrylate, lauryl methacrylate, 2-hydroxyethyl methacrylate, and styrene.

11. The method of claim 8, wherein the monomers forming the biologically active moiety are selected from a group consisting of:

acryloyl-, methacryloyl-, vinyl-, or allyl-modified adducts of superoxide dismutase-mimetics;

acryloyl-, methacryloyl-, vinyl-, or allyl-modified diazenium diolate nitric oxide donors; and

acryloyl-, methacryloyl-, vinyl-, or allyl-modified polycationic peptides.

12. The copolymer of claim 4, wherein the monomers forming the biologically active moiety are is selected from a group consisting of:

acryloyl-, methacryloyl-, vinyl-, or allyl-modified adducts of superoxide dismutase-mimetics;

acryloyl-, methacryloyl-, vinyl-, or allyl-modified diazenium diolate nitric oxide donors; and

acryloyl-, methacryloyl-, vinyl-, or allyl-modified polycationic peptides.